Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 18 March 2014 | By Alexander Gaffney, RAC,
Of all the ways to validate the identity and quality of ingredients used during the course of manufacturing, using your nose isn't among the most advisable.
That piece of wisdom was included in a recent Warning Letter sent by the US Food and Drug Administration (FDA) to a manufacturer of dietary supplements, NJ-based Herbalist and Alchemist, Inc.
FDA's letter indicates that the regulator had inspected the company between 22 October and 16 November 2013, during which time it found manufacturing deficiencies under 21 CFR 111, the Good Manufacturing Practices (GMP) regulation for dietary supplements.
In several instances recounted in the letter, FDA said its inspectors found that the company had failed to use an "appropriate" test or examination to verify the identity of the ingredients used to manufacture its supplements.
The key word there: "appropriate."
FDA noted the company had utilized "organoleptic testing" methods in the course of conducting quality control. Organoleptic refers to the qualities of a substance that can by experienced by sense, such as taste, sight, smell and touch.
In plain terms, the company's employees were reportedly trying to literally sniff out bad ingredients.
This, however, earned the ire of FDA. "An organoleptic test is not a sufficient test for an extract once it is removed from the botanical," FDA observed.
The company had defended its use of the organoleptic testing methods, saying it used the tests to screen for "off odors" that could indicate mold, rancidity or non-plant matter in the raw materials.
However, FDA took issue with this approach. "We do not agree that purity of a botanical ingredient can be determined by smell alone," it wrote. Regulators also noted that purity and identity cannot be determined by smell alone, and require more thorough analytical testing.
The company had reportedly tracked "aromatic aroma" as a proxy for purity for one of its ingredients. Similar test methods were noted, though the exact references were redacted from the report.
Elsewhere in its letter, FDA observed that "'faint, disagreeable aroma' is not a standard [test] or a specific test for purity."
The company was given 15 days in which to respond to FDA's letter.
Warning Letter to Herbalist and Alchemist, Inc
Tags: Scent, Nose, 21 CFR 111, Dietary Supplement, Smell, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.